T1	Participants 48 54	asthma
T2	Participants 228 234	asthma
T3	Participants 1461 1467	asthma
T4	Participants 372 628	79 asthma patients requiring high doses (1,500 microg/d or more) of inhaled beclomethasone dipropionate (BDI) for clinical control (duration of asthma, 11.0 +/- 3.1 yr; duration of BDI treatment, 0.5 +/- 0.3 yr; FEV1 percentage of predicted, 80.7 +/- 2.0%)
